Startup nPharmakon turns drug development upside down

10/3/2012 | MedCityNews.com

Biotech firm nPharmakon has developed a platform that analyzes molecules for their effect on diseases, rather than identifying a specific disease target. The program retargets molecules whose safety has been proven but which have not proved effective against the target disease. nPharmakon works with drugmakers and has found new targets for about 12 drugs.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY